Withings, one of the pioneers of connected health devices, has announced that their upcoming Withings ScanWatch, is their most medically advanced wearable with full FDA clearance. The ScanWatch will be able to monitor heart rate, atrial fibrillation through ECG, breathing disturbances, blood oxygen levels through SpO2, sleep, and physical activity.
The Withings ScanWatch becomes the first wearable to simultaneously be cleared to record ECG & SpO2 measurements.
“ScanWatch received three CES Innovation Awards when it was announced and we are now thrilled to bring it to the United States following robust FDA scrutiny” said Mathieu Letombe, CEO of Withings. “At Withings our core mission is to create beautiful devices people choose to use and wear every day so the medical data they provide can make meaningful impacts on their lives. ScanWatch has been clinically validated to detect AFib and can aid in the detection of breathing disturbances at night, that can be signs of sleep apnea. It is our most ambitious medical watch to date and has the potential to benefit millions of people.”
What makes the ScanWatch so intriguing is that it has actually been developed by medical professionals. Developed by cardiologists and sleep experts, ScanWatch has been validated in two clinical studies. It is designed with a stainless-steel case and durable sapphire glass watch face and features a large digital display as well as easy navigation through a newly created crown dial. Additionally, ScanWatch is water-resistant up to 5 ATM and features an exceptional battery life of up to 30 days.
ScanWatch will be available early November, 2021 from withings.com, Amazon and Best Buy stores. It is priced at $279 (38mm) and $299 (42 mm) and comes in a choice of black or white faces. Customers are encouraged to visit the ScanWatch page on withings.com for early availability news.
